| 초록 |
Cancer immunotherapy, particularly immune checkpoint blockade therapy (ICB), has arisen as a pioneering treatment modality that modulates the host immune system to eradicate tumors. However, significant challenges are still left unsolved, such as limited therapeutic response rates. Recently, nanomedicines have been utilized as representative drug delivery platforms to cancer immunotherapy to improve therapeutic outcomes and minimize side effects. Among various nanomedicines, polymer-based nanomaterials hold great potential in biocompatibility and feasibility for chemical modifications. In this talk, polymeric nanomaterials will be discussed which can be used to enhance the therapeutic outcomes in combination therapy with ICB by remodeling the tumor microenvironments, stimulating immune cells, and inducing immunogenic cell death. |
